Fochon Pharmaceuticals, Ltd. (a Subsidiary of Fosun Pharma) Announces Licensing Agreement with Eli Lilly and Company for Novel Selective BCL-2 InhibitorNovember 4, 2020Read More Fochon Pharmaceuticals Doses First Patient in the US in Phase I Clinical Study of FCN-437, a CDK4/6 Inhibitor for Advanced Solid TumorsJune 26, 2019Read More Fochon Pharmaceuticals Receives CFDA Approval for Clinical Trials of Innovative Medicine to Treat Solid TumorsApril 26, 2018Read More
